Kyverna Therapeutics, Inc. (KYTX)
NMS · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
Kyverna (KYTX) reports positive miv-cel results for Stiff Person Syndrome
# 📰 What This Document Is 🧬 This filing is an 8-K report—a mandatory filing used to announce material corporate events. It is structured as a press release detailing the incredible results of a major clinical trial. You should expect a deep dive into the science, the clinical data, and the company
Kyverna (KYTX) reports miv-cel achieves drug-free gMG remission lasting 52 weeks
# 📰 What This Document Is 🔬 This filing is an 8-K report and accompanying press release from Kyverna Therapeutics. It’s an announcement designed to share highly positive, long-term clinical data on their lead drug candidate, miv-cel. Generally, an 8-K is used to announce material, significant news
SEC filings
All filings →Insider trades
All insider trades →Kyverna Therapeutics, Inc. has no reported insider trades in the last 90 days.